Benitec Biopharma (BNTC) investor relations material

Executive summary

• Advanced BB-301 clinical program with completion of Cohort 1 (low dose) 12-month follow-up and full enrollment of Cohort 2 (high dose), all patients safely treated.

• Held a Type C meeting with the FDA to discuss pivotal study design for BB-301; minutes expected in October.

• Interim clinical results accepted for late-breaking presentation at the ESGCT Congress in October 2026.

• Well-capitalized with $180 million in cash as of June 30, 2026.

Financial highlights

• Total expenses for FY2026 were $51.2 million, up from $41.8 million in FY2025, driven by increased R&D and G&A costs.

• Research and development expenses rose to $23.4 million, mainly due to higher share-based compensation and payroll.

• General and administrative expenses increased to $27.8 million, also due to higher compensation and payroll.

• Net loss attributable to shareholders was $45.5 million ($0.98 per share) for FY2026, compared to $37.9 million ($1.05 per share) in FY2025.

• Cash and cash equivalents stood at $180 million at fiscal year-end.

Outlook and guidance

• Pivotal trial initiation for BB-301 anticipated in mid-2027.

• Interim clinical results to be presented at ESGCT Congress in October 2026.